Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Jul 29

PMID 27467401

Citations 7

Authors

Adriano Curti

Albin Schwarz

Johannes Trachsler

Yuki Tomonaga

Patrice M Ambuhl

Affiliations

Soon will be listed here.

Abstract

Background: High Cut-Off (HCO) dialysis membranes efficiently reduce serum free light chain (FLC) concentrations and may improve renal recovery and survival from multiple myeloma (MM) associated renal failure with cast nephropathy. However, clinical trials comparing dialysis with HCO versus conventional filters are lacking. The aim of this study was to assess clinical outcomes and economic impact of HCO dialyzers compared to conventional hemodialysis membranes in cast nephropathy.

Methods: Multicenter retrospective analysis of 19 patients treated for renal failure from FLC associated cast nephropathy with standard induction chemotherapy (bortezomib/dexamethasone). We compared hemodialysis treatment with High Cut-Off (n = 12) versus conventional dialyzers (n = 7). Primary endpoint was survival; secondary endpoints were renal recovery, renal function and treatment costs.

Results: At 12 months, patient survival was 25% in the HCO group versus 0% in controls (p = NS). A tendency towards faster renal recovery (p = 0.066) and better renal function at 3, 6 and 12 months (p = 0.109) after diagnosis of MM was noted in the HCO group. Complete renal response rate was achieved in 10.5 and 0% of HCO and control patients, respectively, partial renal response in 15.8 and 5.3%, and minor renal response in 26.3 and 15.8%, respectively. Both patient survival and renal recovery were significantly correlated with the extent of free light chain (FLC) reduction in serum. Median treatment costs were CHF 230'000 and 223'000 (p = NS) in the HCO and control group, respectively.

Conclusions: Hemodialysis treatment with HCO membranes for cast nephropathy tended towards better survival as well as faster and better recovery of renal function versus conventional dialyzers. Moreover, total medical costs were comparable between groups. In the absence of results from randomized prospective trials on this topic, the use of HCO dialyzers in patients with renal failure from cast nephropathy may be recommended. Prospective randomized trials are required.

Citing Articles

Extracorporeal light-chain elimination in myeloma with simple medium cutoff membrane hemodialysis: a retrospective cohort study.

Schaaf C, Braunisch M, Holzmann-Littig C, Pfister F, Hannemann L, Hausinger R Front Oncol. 2023; 13:1193504.

PMID: 37746285 PMC: 10514899. DOI: 10.3389/fonc.2023.1193504.

High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury.

Xing Y, Yan J, Yu Z, Zhao J, Wang Y, Li X Front Oncol. 2022; 12:1024133.

PMID: 36387107 PMC: 9645355. DOI: 10.3389/fonc.2022.1024133.

Histological Findings in Kidney Biopsies of Patients with Monoclonal Gammopathy-Always a Surprise.

Klank D, Hoffmann M, Porubsky S, Bergner R Diagnostics (Basel). 2022; 12(8).

PMID: 36010261 PMC: 9406481. DOI: 10.3390/diagnostics12081912.

Effect of high cut-off dialysis for acute kidney injury secondary to cast nephropathy in patients with multiple myeloma: a systematic review and meta-analysis.

Tarragon B, Ye N, Gallagher M, Sen S, Portoles J, Wang A Clin Kidney J. 2021; 14(8):1894-1900.

PMID: 34345412 PMC: 8323139. DOI: 10.1093/ckj/sfaa220.

Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study.

Yadav P, Sathick I, Leung N, Brown E, Cook M, Sanders P Blood Cancer J. 2020; 10(3):28.

PMID: 32127527 PMC: 7054310. DOI: 10.1038/s41408-020-0295-4.

References

Hutchison C, Cockwell P, Reid S, Chandler K, Mead G, Harrison J . Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007; 18(3):886-95. DOI: 10.1681/ASN.2006080821. View

Decourt A, Gondouin B, Delaroziere J, Brunet P, Sallee M, Burtey S . Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis. Clin J Am Soc Nephrol. 2016; 11(3):431-41. PMC: 4791812. DOI: 10.2215/CJN.06290615. View

Johnson W, Kyle R, Pineda A, OBrien P, HOLLEY K . Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990; 150(4):863-9. View

Dimopoulos M, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S . Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010; 28(33):4976-84. DOI: 10.1200/JCO.2010.30.8791. View

Zannetti B, Zamagni E, Santostefano M, De Sanctis L, Tacchetti P, Mancini E . Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Am J Hematol. 2015; 90(7):647-52. DOI: 10.1002/ajh.24035. View

Hutchison C, Bradwell A, Cook M, Basnayake K, Basu S, Harding S . Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009; 4(4):745-54. PMC: 2666427. DOI: 10.2215/CJN.04590908. View

Gonsalves W, Leung N, Rajkumar S, Dispenzieri A, Lacy M, Hayman S . Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015; 5:e296. PMC: 4382661. DOI: 10.1038/bcj.2015.20. View

Zucchelli P, Pasquali S, Cagnoli L, Ferrari G . Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988; 33(6):1175-80. DOI: 10.1038/ki.1988.127. View

Hutchison C, Heyne N, Airia P, Schindler R, Zickler D, Cook M . Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant. 2012; 27(10):3823-8. DOI: 10.1093/ndt/gfr773. View

10.

Basnayake K, Stringer S, Hutchison C, Cockwell P . The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 2011; 79(12):1289-301. DOI: 10.1038/ki.2011.94. View

11.

Heher E, Rennke H, Laubach J, Richardson P . Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013; 8(11):2007-17. PMC: 3817918. DOI: 10.2215/CJN.12231212. View

12.

Knudsen L, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000; 65(3):175-81. DOI: 10.1034/j.1600-0609.2000.90221.x. View

13.

Dimopoulos M, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis M, Repousis P . Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2013; 25(1):195-200. DOI: 10.1093/annonc/mdt483. View

14.

Kyle R, Gertz M, Witzig T, Lust J, Lacy M, Dispenzieri A . Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78(1):21-33. DOI: 10.4065/78.1.21. View

15.

Peters N, Laurain E, Cridlig J, Hulin C, Cao-Huu T, Frimat L . Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study. Hemodial Int. 2011; 15(4):538-45. DOI: 10.1111/j.1542-4758.2011.00587.x. View

16.

Clark W, Stewart A, Rock G, Sternbach M, Sutton D, Barrett B . Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005; 143(11):777-84. DOI: 10.7326/0003-4819-143-11-200512060-00005. View

17.

Hutchison C, Harding S, Mead G, Goehl H, Storr M, Bradwell A . Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs. 2009; 32(12):910-7. DOI: 10.1111/j.1525-1594.2008.00653.x. View

18.

Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens X, Montoto S . Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998; 158(17):1889-93. DOI: 10.1001/archinte.158.17.1889. View

19.

Scheid C, Sonneveld P, Schmidt-Wolf I, van der Holt B, El Jarari L, Bertsch U . Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2013; 99(1):148-54. PMC: 4007933. DOI: 10.3324/haematol.2013.087585. View

20.

Ecotiere L, Thierry A, Debiais-Delpech C, Chevret S, Javaugue V, Desport E . Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant. 2016; 31(5):850. DOI: 10.1093/ndt/gfw056. View